-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
So far, there is no cure for Parkinson's disease (PD) to change the condition
.
PD is related to impaired glucose and energy metabolism, including abnormalities in mitochondrial function and oxidative stress pathways
.
Studies have put forward the hypothesis that improving glycolysis may be beneficial for PD.
Cai et al.
studied terazosin, which is usually used to treat the urinary symptoms of benign prostatic hyperplasia (BPH)
.
Terazosin acts as an α1-adrenergic (A1A) receptor antagonist and phosphoglycerate kinase 1 activator (PGK1a)
.
PGK1as activates an enzyme involved in the production of ATP during glycolysis
Terazosin has neuroprotective properties in cells and animal models of PD
.
A retrospective evaluation of the human cohort showed that people taking PGK1as had better results than tamsulosin (a non-PGK1a that is also used to treat benign prostatic hyperplasia)
In this way, Priti Gros and others of the University of Toronto in Canada tried to verify these results in a large cohort with a long follow-up time
.
They used the health database to explore the relationship between exposure to PGK1as and the incidence of PD
Specifically: Their retrospective cohort study included men over the age of 66 who were newly exposed to phosphoglycerate kinase 1 activator or tamsulosin, and compared their incidence of PD using health care administrative data from Ontario, Canada
.
.
Their retrospective cohort study included men over the age of 66 who were newly exposed to phosphoglycerate kinase 1 activator or tamsulosin, and compared their incidence of PD using health care administrative data from Ontario, Canada
There is no significant difference in these hazards (P = 0.
2094)
.
The secondary analysis with 6 months later and 1, 2 years later as the observation window also showed similar results
.
.
The secondary analysis with 6 months later and 1, 2 years later as the observation window also showed similar results
Original source:
Gros P, Wang X, Guan J, et al.
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
Mov Disord.
Leave a message here
